Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 289

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 289
---
 licensing opportunities (both in-licensing and out-licensing), and M&A opportunities; |

| • |     | establishing, approving, modify, monitoring and directing the process and procedures related to the review and evaluation of certain potential strategic transactions and determining whether to proceed with any such process, procedures, review or evaluation; and |

| • |     | determining on behalf of the Board and the Company whether a possible strategic transaction is advisable and is fair to, and in the best interests of, the Company and its stockholders (or any subset of the stockholders of the Company that the C&T Committee determines to be appropriate), rejecting or approving a possible strategic transaction, or recommending such rejection or approval to the Board, approving or recommending to the Board the consummation of a possible strategic transaction, and reviewing, evaluating and monitoring proceedings and activities of the Company related to certain potential strategic transactions. |

Under its charter, the C&T Committee may form, and delegate authority to, subcommittees as appropriate. The C&T Committee reviews, discusses and assesses its own performance at least annually. The C&T Committee also periodically reviews the charter of the C&T Committee and the compliance procedures in place to implement such charter and recommend necessary clarifications or changes to such charter to the Board for approval. Code of Business Conduct and Ethics Semnur has adopted a written code of business conduct and ethics, which apply to Semnur’s directors, officers and employees, including Semnur’s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of Semnur’s code of business conduct and ethics is be posted on its website at www.semnurpharma.com. Information contained on or accessible through such website is not a part of this prospectus, and the inclusion of the website address in this prospectus is an inactive textual reference only. Semnur intends to disclose any amendments to its code of business conduct and ethics, or any waivers of its requirements, on its website to the extent required by the applicable rules and exchange requirements. Compensation Committee Interlocks and Insider Participation None of the members of Semnur’s Compensation Committee is currently, or has been at any time in the past year, one of Semnur’s officers or employees. Other than Mr. Ma, Dr. Ji and Mr. Shah, none of Semnur’s executive officers currently serves, or has served during the last year, as a member of the board of directors or Compensation Committee of any entity that has